Skip to main content
. 2022 Jan 5;88(5):2169–2179. doi: 10.1111/bcp.15141

FIGURE 1.

FIGURE 1

Contribution of post‐approval confirmatory trials to the demonstrated clinical benefit of converted CMA cancer indications, reflected by change in ESMO‐MCBS score Colours of the connections between the time points indicate whether clinical benefit increased (green), remained the same (grey), or decreased (red). ESMO‐MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale